Bionow is the life-sciences membership organisation for the North of England and supports business growth, competitiveness and innovation within the biomedical and life science sectors. Bionow’s membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses.
BioPartner UK is an independent UK trade organisation, working with government and private agencies to promote UK expertise and provide practical support for those trading overseas.
BioPartner is your point-of-contact for the UK delegation at Bio-Europe 2014.
Cambridge Bioscience is a well established, leading European distributor of life science products bringing new and exciting technologies to researchers. Working with over forty specialist suppliers around the world, we offer an innovative, extensive and diverse range of over 450,000 products, services and instruments supporting research in the areas of drug discovery, regenerative medicine, cell culture and much more.
The products and services Cambridge Bioscience offers includes:
· Ion Channel, GPCR & Kinase Profiling Services
· Primary screening & Secondary Drug Profiling Services
· Cardiac Safety Assessment
· Ion Channel & GPCR Cell Lines
· Human Tissues, TMAs & Biofluids
· Primary Cells & Cell Culture Technologies
To find out more, please meet us at the event or contact us using the details below
Tel: +44 (0)1223 316 855
Fax: +44 (0)1954 781 323
Established in 1982, Chiltern is a leading global clinical CRO offering specialized services in all phases of oncology, hematology and a range of other therapeutic areas, together with global sourcing and functional service provider (FSP) solutions. Chiltern’s 2,100 people work in more than 40 countries and offer expertise, engagement and tailored, responsive solutions to meet the demands of biotech and pharmaceutical partners of all sizes.
Ms Juliette AlmondGlobal Manager, Client Services - oncology
Ms Andrea Cotton-BerryGlobal Director, Client Services - Oncology
Mr Michael BakerVP, Oncology
Mr Lewis CameronGlobal Head, Oncology
Clinical Network Services (UK) Ltd
Clinical Network Services (CNS) is an Australian, New Zealand and UK based service group, offering full and integrated drug development consultancy to small – medium sized Biotech companies from inception through to end of phase II clinical trial programs. CNS offers a unique service that brings together BioDesk; an intelligent product development and regulatory planning service, with our highly experienced regional clinical operations and data management teams.
BioDesk is a team of in-house scientists and commercial drug development experts, who work closely with our clients from the earliest of planning stages. Together they create and manage Drug Development Plans, including all stages of pre-clinical/CMC programs that embrace global regulatory strategies whilst leveraging our unique regional advantage.
Australia and New Zealand have an outstanding product development timeline advantage due to our access to a pragmatic regulatory environment that makes it possible to add value to the global regulatory dossier and enter the clinic quickly, without the need for prior approval from another regulatory agency. Our clients have often established initial proof-of-concept quickly, and have enjoyed a time(cost) saving when compared to the more resource-intensive strategy of applying for an IND or CTA.
CNS has worked with clients whose cumulative acquisition price exceeds US$16.5billion; many of these clients initially fast-tracked their programs by running their phase 1 & 2 studies in Australia and New Zealand.
Further information on CNS can be found at www.clinical.net.au
Based on the ground breaking Nature publication ‘Automated design of ligands to polypharmacological profiles’ and with several commercial collaborations underway ex scientia is the first company to develop a systematic approach to tailoring drugs against polypharmacology profiles for superior clinical efficacy. We are exploiting our advanced technologies to develop compounds with tailored selectivity and in particular a portfolio of efficacious bispecific drugs.
Our bispecific design technology delivers efficacious small molecule drugs binding novel target combinations, either within or between gene families. By hitting multiple nodes in the cellular network simultaneously better clinical efficacy can be achieved.
Non-specific, promiscuous interactions with undesired proteins frequently cause drug toxicity and adverse effects. Our tailored selectivity technology can be applied to the discovery of drug candidates with desired selectivity, thereby reducing side effects and toxicity.
Advances in phenotypic screening are opening new ways to deliver improved medicines. Our phenotypic design technologies can generate and optimise effective molecules using high content phenotypic data without prior consideration of the targets.
Professor Andrew HopkinsCEO
Dr Mark SwindellsChief Operating Officer
Dr Denise BarraultChief Commercial Officer
Fusion Antibodies is a CRO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.
Meet with potential companies looking to access our royalty free, fee-for-service antibody engineering expertise in:
Transient & Stable cell line development
We are also seeking partnerships with companies interested in the area of EGFR pathway to develop our in-house double targeting humanized therapeutic Antibody Fsn1006.
Glythera Limited is a biotechnology company specializing in the development of platform technologies for next generation biotherapeutics. We have 2 core programmes:
- PermaLink™ - a novel, stable, highly cysteine-specific conjugation platform for antibody drug conjugates (ADCs)
PermaLink™ is associated with enhanced anti-tumour activity in vivo vs maleimide in comparative ADC models. It is suitable for cleavable and non-cleavable systems
- PermaCarb™ - a novel sialylation correction platform which can (i) improve bioavailability & enhance product performance and (ii) remove the issue of sialic acid contamination. It is particularly appropriate for the development of biobetters and biosimilars
PermaCarb™ has been validated vs several biotherapeutics, including FSH and etanercept
Based in the NE of England, Glythera has dedicated bioprocessing and chemistry laboratories enabling us to conduct in-house evaluations for our partners to progress applications of PermaLink™ and PermaCarb™ technologies.
We are seeking license collaborations for PermaLink™ and out-license partners for PermaCarb™
Illetrop commercialises products and services in diverse fields including in oncology, inflammatory diseases, primary cells and antibodies.